The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
TCT 2021 | Updates on transplant for patients with myeloma
Sergio A. Giralt, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, provides an overview of the latest developments in the field of multiple myeloma, including depth of response associated with a four-drug induction, as well as the use of combined carfilzomib lenalidomide maintenance therapy as evaluated in a recent study. Dr Giralt continues to discuss the role of allogeneic transplantation in patients with multiple myeloma and highlights the need for a better understanding of how to sequence therapies for patients. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
